• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

EAGeR RCT Follow-Up: Low-Dose Aspirin for Preventing Pregnancy Loss

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • In the EAGeR Trial (Effects of Aspirin on Gestation and Reproduction), preconception-initiated low-dose aspirin therapy did not decrease the risk of pregnancy loss
    • ‘Intention-to-treat’ results could be impacted by nonadherence
  • Naimi et al. (Annals of Internal Medicine, 2021) re-analyzed EAGeR data, estimating per protocol effects of preconception-initiated low-dose aspirin on pregnancy loss and live birth

METHODS:

  • Prospective cohort study based on EAGeR trial
  • Participants
    • Women aged 18 to 40 attempting pregnancy
  • 1 or 2 previous pregnancy losses
  • Intervention
    • Low-dose aspirin: 81 mg
    • Placebo
  • Study design
    • Adherence to intervention was assessed by measuring pill bottle weights at regular intervals during follow-up
    • Outcomes were determined using pregnancy tests and medical records
  • Primary outcome: Live birth
  • Secondary outcomes
    • hCG-detected pregnancies
    • Pregnancy losses

RESULTS:

  • 1227 women
    • Aspirin group: 615
    • Placebo: 613
  • Compared to placebo, adherence to low-dose aspirin over the entire follow-up period was associated with
    • Increased hCG-detected pregnancies: Relative risk (RR) 1.12 (95% CI, 1.02 to 1.23)
    • Fewer pregnancy losses: RR 0.69 (95% CI, 0.50 to 0.95)
    • Increased live births: RR 1.33 (95% CI, 1.08 to 1.64)
  • Delayed postconception initiation of low-dose aspirin therapy led to a reduction in the estimated effects especially for pregnancy loss
    • 6 weeks after conception: RR 0.70 (95% CI, 0.47 to 1.04)
    • 10 weeks after conception: RR 0.93 (95% CI, 0.65 to 1.33)
  • Live birth: Effects were greater if treatment initiated before conception and continued throughout pregnancy vs starting aspirin >6 weeks
  • Effects were obtained if participants adhered at a minimum of 4 days per week

CONCLUSION:

  • In this study based on the EAGeR RCT, women with 1 to 2 previous losses who were adherent in their use of low dose aspirin for at least 4 days per week had an increase in live births greater than 30% vs placebo in subsequent pregnancy
  • In addition, the authors conclude

Our study is the first to our knowledge to shed light on the optimal timing of LDA therapy, suggesting maximum benefits by initiating treatment before and early in pregnancy

Learn More – Primary Sources:

The Effect of Preconception-Initiated Low-Dose Aspirin on Human Chorionic Gonadotropin–Detected Pregnancy, Pregnancy Loss, and Live Birth

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

ASPIRIN RCT Results: Low-Dose Aspirin in Early Pregnancy and Impact on Preterm Delivery and Perinatal Mortality
Stillbirth Management: The ACOG SMFM Consensus Document
ASPRE Trial: A Combined Risk Algorithm and Use of Aspirin to Prevent Preterm Preeclampsia
Is There a Link Between Aspirin Use in Pregnancy and Increased Risk of Bleeding Complications?
Physical Activity and Time-to-Pregnancy in Women with a History of Pregnancy Loss

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site